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Abstract Once a large proportion of the genes responsible for
genetic disorders are identified in the post-genome era, the
fundamental challenge is to establish a genotype/phenotype
relationship. Our aim is to explain how mutations in a given
gene affect its enzymatic function and, in consequence, disturb
the life of the cell. Genome integrity is continuously threatened
by the occurrence of DNA damage arising from cellular exposure
to irradiation and genotoxic chemicals. This mutagenic or
potentially lethal DNA damage induces various cellular
responses including cell cycle arrest, transcription alteration
and processing by DNA repair mechanisms, such as the
nucleotide excision repair (NER) pathway. Disruption of NER
in response to genotoxic injuries results in autosomal recessive
hereditary diseases such as Xeroderma pigmentosum (XP),
Cockayne syndrome (CS) and trichothiodystrophy (TTD). One
of the most immediate consequences of the induction of strand-
distorting lesions is the arrest of transcription in which TFIIH
plays a role in addition to its role in DNA repair. The
observations made by clinicians close to XP, TTD and CS
patients, suggested that transcription defects responsible for
brittle hair and nails for TTD, or developmental abnormalities
for CS, resulted from TFIIH mutations. Here a story will be
related which could be called ‘a multi-faceted factor named
TFIIH’. As biochemists, we have characterized each component
of TFIIH, three of which are XPB and XPD helicases and cdk7,
a cyclin-dependent kinase. With the help of structural biologists,
we have characterized most of the specific three-dimensional
structures of TFIIH subunits and obtained its electron micro-
scopy image. Together these approaches help us to propose a
number of structure^function relationships for TFIIH. Through
transfection and microinjection assays, cell biology allows us to
determine the role of TFIIH in transcription and NER. We are
thus in a position to explain, at least in part, transcription
initiation mechanisms and their coupling to DNA repair. We now
know how the XPB helicase opens the promoter region for RNA
synthesis and that one of the roles of XPD helicase is to anchor
the cdk7 kinase to the core-TFIIH. In XP and CS associated
patients, we have demonstrated that some XPD mutations
prevent an optimal phosphorylation of nuclear receptors by
cdk7 with, as a consequence, a drop in the expression of genes
sensitive to hormone action. We have thus shown that hormonal
responses operate through TFIIH. Careful analysis of each
TFIIH subunit also shows how the p44 Ring finger participates in
certain promoter escape reactions. We are also able to localize
the action of TFIIH in the sequence of events that lead to the
elimination of DNA lesions. Thanks to the combination of these
different approaches we are obtaining a much clearer picture of
the TFIIH complex and its integration into the life of the
cell. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
1. Introduction
The synthesis of messenger RNA in eukaryotes by RNA
pol II is a key step in the gene expression pathway which
conditions the ‘normal’ life of a cell and the development of
an individual. Accurate synthesis will depend not only on the
integrity of the gene to be transcribed but also on the numer-
ous factors involved in the various processes that allow
mRNA synthesis and, thereafter, the production of biologi-
cally active proteins. Dysregulation of this pathway results in
di¡erent disorders in man. On the one hand, mutations that
a¡ect components of the transcription apparatus including the
RNA polymerases, their associated factors and/or their target
sites will lead to genetic disorders, some of which are already
identi¢ed [1]. On the other hand, the inaccurate repair of
damage encountered on the transcribed strand of a given
gene, will either modify the rate of RNA synthesis and/or
the nature (the quality) of the RNA. Such inaccurate DNA
repair may be at the origin of mutations. Damage on the
transcribed strand may also stop RNA pol II, although it is
also possible that RNA pol II reading through the damaged
DNA will lead to the production of modi¢ed proteins. Defects
in the mechanism which couples transcription to repair gives
rise in humans to phenotypes associated with the Cockayne
syndrome (CS) genetic disorders.
In this review, I will focus on TFIIH, a factor involved in
both transcription and DNA repair [2^4]. I will try to dem-
onstrate how, having at hand several biochemical assays and
observations of patients by clinicians, we were able not only
to establish genotype/phenotype relationships, but also to bet-
ter understand the mechanism of transcription initiation and,
to a certain extent, DNA repair. Our work was facilitated by
the discovery that mutations in two subunits of TFIIH were
at the origin of Xeroderma pigmentosum (XP), previously
de¢ned as DNA repair disorders. XP results from mutations
in the XPB and XPD helicases, the two largest subunits of
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TFIIH, and exhibits several clinical features such as UV-sen-
sitivity, cutaneous hyperpigmentation and a skin cancer pre-
disposition, neurodegeneration and progressive mental retar-
dation that may also be attributed to transcriptional de¢cien-
cies. In some cases, XP presents clinical features characteristic
of CS, caused by a dysfunction in the CSA and CSB proteins
which, it has been suggested, are involved in the coupling
between transcription and nucleotide excision repair (NER).
Indeed, it was found a few years ago that in the case of
genotoxic attack, actively transcribed genes are preferentially,
and therefore more rapidly, repaired than the non-transcribed
ones [5,6]. The most commonly described features of CS are a
moderate UV-sensitivity without cancer proneness, growth
retardation (especially cachectic dwar¢sm), sexual immaturity,
neurodysmyelination and progressive mental degeneration. In
other cases the XPB and XPD proteins are associated with
trichothiodystrophy disorder (TTD). The most typical clinical
features of these patients are brittle hair and nails. With the
exception of photo-sensitivity, this large spectrum of symp-
toms cannot be explained by a DNA repair defect alone but
might also re£ect a transcriptional de¢ciency.
In fact the TFIIH story started in 1989 [7], when within the
framework of our studies on the mechanisms that govern
transcription initiation, we attempted to purify a factor, at
¢rst named BTF2, from a protein fraction which was shown
to be indispensable to restore basal transcription activity in
vitro. Starting from 500 l of HeLa cells, it took two and a half
years at +4‡C to obtain, after seven puri¢cation steps, a pro-
tein complex containing nine polypeptides ranging from 90 to
30 kDa. The following steps would have been simply to char-
acterize each of the nine subunits (Fig. 1), if we had not
identi¢ed ERCC3/XPB, an excision repair cross complemen-
tary protein [8], involved in NER and thus part of the DNA
repair apparatus set in action upon genotoxic attack [9]. Was
this a contamination, an artefact or a bona ¢de partner of the
large TFIIH complex? An antibody directed against XPB,
proved that this subunit was indeed part of TFIIH and that
it was, according to in vivo microinjection experiments and in
vitro reconstituted systems, implicated in both NER and tran-
scription [10]. This ¢nding helped to establish de¢nitively the
connection between transcription and repair which in fact had
been suspected for several years. This also explained the rarity
of XPB patients as most of the mutations in this gene would
be incompatible with life. With the motto, ‘‘one polypeptide
per student and/or post-doc’’, we have identi¢ed each of the
nine subunits of TFIIH [11,12]; one was XPD, a helicase [13]
in which a mutation gives rise to another form of XP (the
XPD group). Again our work stimulated enthousiasm when
we identi¢ed cdk7 (a cyclin-dependent kinase) as part of
TFIIH and thus responsible for phosphorylation of the car-
boxy-terminal domain (CTD) of the largest subunit of RNA
pol II [14^16]. Whether the fact that the TFIIH kinase is
cyclin-dependent re£ects a connection between TFIIH as a
repair factor and being involved in cell cycle regulation, re-
mains to be further documented.
2. TFIID: a three-dimensional (3D) picture
Having the possibility to produce recombinant as well as
endogeneous TFIIH, one of our objectives was to establish
the structure^function relationships of TFIIH. This would
also allow the design of drugs that can interfere with the
enzymatic activities of TFIIH and could circumvent the tran-
scription and/or NER defects observed in XP patients. Up to
now we have failed to obtain a crystal structure of TFIIH. We
have, however, characterized most of the speci¢c 3D struc-
tures of the TFIIH subunits [17,18]. We also succeeded in
preparing a highly puri¢ed and concentrated human TFIIH
fraction to obtain electron microscopy pictures. The 3D mod-
el designed from electron microscopy analysis shows that
TFIIH is organized into a ring-like structure, with a hole
whose size is able to accommodate a double-stranded DNA
molecule, and from which an almost spherical bulge of pro-
tein density protrudes out [19,20]. The human recombinant
core-TFIIH subcomplex, which only contains ¢ve subunits,
has a circular architecture that can be superimposed on the
ring found in human TFIIH, suggesting that the cdk-activat-
ing kinase (CAK) constitutes the protruding domain. The
quaternary organization of TFIIH subunits can be partially
inferred from immunolabeling combined with co-immunopre-
cipitation experiments. The cdk7 kinase was shown to be lo-
cated in the protruding domain, whereas p44 is located within
the ring structure, at the basis of the protruding protein den-
sity, and is £anked on either side by the XPB and XPD hel-
icases. It is interesting to note that the location of XPD, close
to the CAK-containing bulge, is consistent with the proposal
that it could bridge (or stabilize) the interaction between the
CAK and the core-TFIIH. Such information will also explain
some defects within XPD patients (see below). The discrep-
ancies in the subunit composition and quaternary organiza-
tion between the yeast and human TFIIH subcomplexes [21]
probably re£ect some subtle di¡erences concerning the role of
their various subunits in the DNA repair and transcription
activities of TFIIH.
Once the TFIIH subunits had been identi¢ed, we investi-
gated their role in both transcription and NER [22,23]. This
work was made possible due to the availability of TFIIH
immunopuri¢ed from the numerous cell lines derived from
XPB and XPD patients. In addition we had set up in vitro
assays to evaluate not only transcription and NER activity
but also helicase activity [24]. Moreover, we are now able to
overexpress recombinant TFIIH with mutations in any of the
subunits, using the baculovirus/insect cell systems [25].
3. XPB, the helicase of transcription
Once the pre-initiation complex is formed (upon arrival of
the last basal transcription factor), opening of the promoter
around the start site occurs in an ATP-dependent manner toFig. 1. Summary of the enzymatic functions of TFIIH subunits.
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allow further reading of the coding strand by RNA pol II [26].
This function is mainly due to the ATP-dependent XPB heli-
case (Fig. 2). Whether such an opening is regulated by pro-
teins of either the TFIIH factor, the pre-initiation complex,
the activation machinery or external stimuli is not yet clear.
However, another subunit, p52 exhibits some connections
with XPB since it allows its integration within TFIIH (our
unpublished data). One may also wonder as to the conse-
quence of the interaction with XPB and stimulation by TFIIE
of the ATPase and kinase activities of TFIIH on the tran-
scription reaction [27]. One should mention that XPG, an
endonuclease involved in DNA repair, also targets XPB.
This may explain some of the clinical features observed in
XPG patients (having a mutation in the XPG) which have
not yet been investigated. These observations, however,
should not obscure the crucial role of XPB in the DNA repair
reaction, in which it allows the opening around the DNA
damage [28]. However, it is clear that abolishing the XPB
helicase function, by mutating its ATP binding site, com-
pletely abolishes its function in both transcription and DNA
repair [25].
4. A secondary role of XPD: opening and anchoring
The mammalian TFIIH revealed a highly conserved struc-
ture and function from yeast to man which can be resolved
into several functional subcomplexes: the core-TFIIH, com-
posed of ¢ve subunits (XPB, p62, p52, p44 and p34), and the
CAK, composed of cdk7, cyclin H and MAT1. The remaining
XPD helicase subunit can be found associated with either the
core-TFIIH or the CAK and is believed to bridge CAK to the
core-TFIIH. Beside its helicase activity, XPD allows anchor-
ing of CAK to the core-TFIIH (Fig. 2) through an interaction
with p44, another subunit of TFIIH [29]. Upon interaction
with p44, XPD helicase activity increases. Contrary to what
was observed with XPB, XPD is dispensable for the transcrip-
tion reaction: TFIIH that carries a mutation in the XPD heli-
case ATP binding site or that lacks the XPD subunit, allows
(although to a lower extent) RNA synthesis, when added to
an in vitro transcription assay that contains all the basal tran-
scription factors. It is clear, however, that when XPD is
present, it allows CAK anchoring to TFIIH and optimal tran-
scriptional activity. Mutations in XPD or in p44 which mod-
ify the XPD^p44 interaction strongly modulate the composi-
tion of TFIIH by a¡ecting the overall architecture of TFIIH
[30]. It is also interesting to note the additional role of p44 in
promoter escape. Indeed, mutations that abolish the ring ¢n-
ger structure of p44 allow the ¢rst phosphodiester bond for-
mation, when the mutated recombinant TFIIH is added to an
in vitro transcription assay, but reduce RNA elongation.
5. Phosphorylation by CAK is essential
Most basal transcription factors are phosphorylated (at
least in vitro). Cyclin H and cdk7, part of CAK, are sub-
strates for other cyclin-dependent kinases [31], whereas they
phosphorylate components of the transcription machinery.
The CTD of the largest subunit of RNA pol II, which con-
tains several repeats of a serine/threonine-rich heptapeptide,
represents an ideal substrate for serine/threonine kinases.
CTD phosphorylation/dephosphorylation follows certain
steps of the transcription reaction. Indeed it has been demon-
strated that RNA pol II engaged in the elongation step, is
hyperphosphorylated, whereas initiation requires a hypophos-
phorylated RNA pol II [32]. Mutations in either cdk7 or
MAT1 decrease both CTD phosphorylation and basal tran-
scription (Fig. 2). How this phosphorylation process is con-
nected with the other (helicase and ATPase) enzymatic func-
tions of TFIIH and the transcription complex is not yet
established. In fact, in vitro CTD phosphorylation requires
neither promoter opening nor formation of the ¢rst phospho-
diester bond: CAK stimulates signi¢cantly the synthesis of the
¢rst phosphodiester bond; this involves only a structural con-
tribution of the complex and not its enzymatic activity [33].
Since transcription regulators interact directly, or via co-
factors, with the basal transcription machinery, it was hy-
pothesized that kinases such as cdk7, present within this ma-
chinery, would participate in the regulation of transcription.
Fig. 2. TFIIH at the crossroad of transcription, DNA repair and cell cycle regulation.
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As a consequence, one could observe variations in gene ex-
pression levels. It was found that the retinoic acid and the
estrogen receptors are phosphorylated by TFIIH and that
this phosphorylation parallels an increase of target gene ex-
pression level [34,35]. Indeed phosphorylation might regulate
either the binding of the receptor to its responsive element
and/or its dimerization. Upon interaction with TFIIH and
further phosphorylation, these DNA binding proteins could
stimulate some steps of the transcription reaction such as
CTD phosphorylation, DNA opening, promoter clearance,
or recruitment and/or stimulation of the elongation machi-
nery.
Little is known concerning the role of CAK in DNA repair
and there are some discrepancies in the literature. On the one
hand, studies in yeast demonstrated that the kinase Kin28 (the
counterpart of cdk7), is not required for in vitro NER [36].
On the other hand, inhibition of CAK activity was shown to
restore DNA repair [23].
6. TFIIH: at the origin of transcription syndrome
Microinjection of either highly puri¢ed TFIIH or even
TFIIH reconstituted from recombinant subunits expressed in
a baculovirus system is able to complement the NER defect in
XPD and XPB as well as TTD-A ¢broblasts [10]. These syn-
dromes are due to defects of TFIIH in one of its enzymatic or
other structural functions, which might inhibit not only NER
but also transcription. We thus demonstrated that mutations
in the CTD of the XPD subunit (which represents more than
70% of the mutations found in XPD patients), disturb the
architecture of TFIIH through a decrease in the interaction
between the XPD and the p44 subunits [29]. This results in the
abrogation of the stimulatory (or regulatory) function of p44
towards the XPD helicase within TFIIH which then cannot
eliminate the DNA damage, thus explaining the NER defect
observed in those patients. Moreover, the weakening of the
p44/XPD interaction might have additional consequences on
the cdk7 kinase activity which is associated with the core-
TFIIH through XPD. Indeed, modi¢cation of the TFIIH ar-
chitecture would not allow optimal transcription activity:
modi¢cations of the phosphorylation of either CTD or
DNA binding proteins such as nuclear receptors (unpublished
data) also decrease in vivo as well as in vitro transcription,
thus explaining some phenotypes of the XPD patients.
We have also shown that TFIIH isolated from patients
bearing a mutation in the 5P-end of XPB is de¢cient in its
ability to open either the promoter or the DNA around the
lesion [24]. Under these conditions, beside the NER defect,
RNA pol II is unable to accurately synthesize RNA thus
explaining the severity of the XPB phenotype and the low
number of XPB patients.
The genetic defect in TTD-A is unknown, but caused by
dysfunctioning TFIIH. Surprisingly none of the TFIIH sub-
units carries a mutation and immunopuri¢ed TFIIH from
TTD-A cells is active in both transcription and repair [37].
Immunoblot and immuno£uorescence analyses reveal a strong
reduction in the TFIIH concentration. Thus, the phenotype of
TTD-A appears to result from sublimiting amounts of TFIIH,
probably due to a mutation in a gene determining the complex
stability. Not only the identity of the gene but also its poten-
tial function remains obscure. It is likely that the molecular
defect resides in either translation, complex assembly, post-
translational modi¢cation (including conversion of TFIIH
from transcription into NER mode and vice versa) or in-
creased proteolytic degradation, all of which can in£uence
steady-state levels of TFIIH. It cannot be excluded however
that the TTD-A defect does not reside in TFIIH itself but in
an endogeneous cellular factor causing rapid inactivation of
the injected TFIIH.
There we are. Fig. 2 is incomplete. Several questions remain
unanswered. How the enzymatic functions of TFIIH are regu-
lated in transcription, DNA repair and cell cycle regulation?
What the connection is between these three mechanisms? How
TFIIH crosses from transcription to DNA repair? Is CAK a
check point between DNA repair and cell cycle arrest? An-
swering these questions is our challenge to understand gene
expression regulation and especially the connection between
transcription and repair.
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